Sacituzumab tirumotecan (sac-TMT) significantly improved progression-free survival compared to chemotherapy in HR-positive, HER2-negative breast cancer patients. Sac-TMT reduced the risk of disease ...
Sacituzumab tirumotecan (sac-TMT) significantly improved progression-free survival compared to chemotherapy in HR-positive, HER2-negative breast cancer patients. Sacituzumab tirumotecan significantly ...
Neoadjuvant Enhertu then THP improved pathological complete response rate in patients with high-risk, HER2-positive early ...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical ...
T-DXd significantly improved IDFS and reduced the risk of invasive disease or death by 53% compared to T-DM1 in high-risk, HER2-positive breast cancer patients. The trial demonstrated superior ...
ENHERTU Followed by THP Before Surgery Resulted in Pathologic Complete Response in 67% of Patients w/High-Risk HER2 Positive ...
Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated ...
PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial is fully enrolledAdditional analysis of data from a Phase 1b clinical trial that included all patients treated with gedatolisib combined ...
Roche’s giredestrant was shown to reduce the risk of breast cancer progression or death by 62% for a specific cohort of a ...
BERLIN -- For the first time in a phase III trial, adjuvant treatment with a CDK4/6 inhibitor significantly improved overall ...
Discover how the neoadjuvant T-DXd-THP regimen significantly improves complete response rates and safety over standard ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback